Drug Profile


Alternative Names: 485232; IL-18 - GlaxoSmithKline; Interleukin-18 - GlaxoSmithKline; Recombinant human interleukin-18 - GlaxoSmithKline; rhIL-18; SB-485232

Latest Information Update: 16 Jul 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hayashibara Biochemical Laboratories; Hyogo College of Medicine
  • Developer GlaxoSmithKline
  • Class Antineoplastics; Cytokines
  • Mechanism of Action Interleukin 18 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Non-Hodgkin's lymphoma; Ovarian cancer
  • Discontinued Cancer; Malignant melanoma

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Non-Hodgkin's-lymphoma(Combination therapy) in USA (IV, Infusion)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Ovarian-cancer(Combination therapy) in USA (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top